Alpha-internexin expression in gliomas: relationship with histological type and 1p, 19q, 10p and 10q status

Durand, Karine; Guillaudeau, Angélique; Pommepuy, Isabelle; Mesturoux, Laura; Chaunavel, Alain; Gadeaud, Emilie; Porcheron, Marion; Moreau, Jean-Jacques; Labrousse, François

doi:10.1136/jcp.2010.087668

Cited by 18 publications

(7 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our series, glioblastomas and oligodendrogliomas were strongly labeled by both Ext-Ab and Int-Ab, whereas oligoastrocytomas were moderately or strongly labeled by Ext-Ab but weakly by Int-Ab. Thus, in combination with other markers such as Olig2, p53 or 1p19q deletion, the study of EGFR expression might be useful to further characterize the diffuse gliomas (32–36). …”

Section: Discussionmentioning

confidence: 99%

Adult diffuse gliomas produce mRNA transcripts encoding EGFR isoforms lacking a tyrosine kinase domain

Guillaudeau

Durand²,

Rabinovitch-Chable³

et al. 2011

International Journal of Oncology

View full text Add to dashboard Cite

The epidermal growth factor receptor (EGFR) gene encodes four alternatively spliced mRNA, variants 1, 2, 3 and 4, respectively, encoding the whole isoform a (EGFR) and truncated isoforms b, c and d, all of which lack the receptor’s intracellular domain. In addition, a mutant EGFRvIII differs from isoform a in a truncated extracellular domain. The expression pattern of these isoforms is unknown in adult diffuse gliomas. Thus, we investigated in 47 cases: i) EGFR protein expression by immunohistochemistry using an extracellular domain-recognizing antibody (Ext-Ab) and an intracellular domain specific one (Int-Ab), ii) mRNA expression of EGFRv1, -v2, -v3, -v4 and -vIII by RT-PCR and iii) EGFR amplification by fluorescent in situ hybridization. The relation of these data with histological criteria and patient outcome was studied. The immunostaining was stronger with the Ext-Ab than with the Int-Ab. EGFRv1, -v2, -v3 and -v4 mRNA expression were highly correlated. They were expressed in all tumors, with highest levels in glioblastomas. EGFRv1 strong levels and the presence of vIII mRNAs were more closely associated with Int-Ab staining. EGFR gene amplification concerned only glioblastomas and was associated with the presence of EGFRvIII and high levels of EGFRv2, -v3 and -v4 transcripts. A pejorative outcome was associated with: histology (glioblastomas), EGFR amplification, strong Int-Ab labeling and high levels of variant mRNAs. Our results indicated that the full-length EGFR and mutant EGFRvIII are not the sole EGFR isoform expressed in diffuse gliomas. This could explain discordant immunohistochemical results reported in the literature and may have therapeutic implications.

show abstract

Section: Discussionmentioning

confidence: 99%

Adult diffuse gliomas produce mRNA transcripts encoding EGFR isoforms lacking a tyrosine kinase domain

Guillaudeau

Durand²,

Rabinovitch-Chable³

et al. 2011

International Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…As far as we investigated, there are no reports elucidating the direct link in GB. Possible explanation might be that, not only the MIB-1 LI, GB has been reported to contain several abnormalities of molecular parameters, including 1p19q deletion status [21,22], isocitrate dehydrogenase (IDH) genes mutation status [23,24], or methylation status of the O6-methylguanine-DNA methyltransferase gene MGMT promoter methylation status [25-27]. On the contrary, increased cell cycling and MIB-1 LI suggest more aggressive behavior of promote tumor progression and metastasis in variety of cancers [28,29].…”

Section: Discussionmentioning

confidence: 99%

Patterns of failure after multimodal treatments for high-grade glioma: effectiveness of MIB-1 labeling index

et al. 2012

View full text Add to dashboard Cite

BackgroundThe purpose of the present study was to analyze the recurrence pattern of high-grade glioma treated with a multimodal treatment approach and to evaluate whether the MIB-1 labeling index (LI) could be a useful marker for predicting the pattern of failure in glioblastoma (GB).Methods and materialsWe evaluated histologically confirmed 131 patients with either anaplastic astrocytoma (AA) or GB. A median dose was 60 Gy. Concomitant and adjuvant chemotherapy were administered to 111 patients. MIB-1 LI was assessed by immunohistochemistry. Recurrence patterns were categorized according to the areas of recurrence as follows: central failure (recurrence in the 95% of 60 Gy); in-field (recurrence in the high-dose volume of 50 Gy; marginal (recurrence outside the high-dose volume) and distant (recurrence outside the RT field).ResultsThe median follow-up durations were 13 months for all patients and 19 months for those remaining alive. Among AA patients, the 2-year progression-free and overall survival rates were 23.1% and 39.2%, respectively, while in GB patients, the rates were 13.3% and 27.6%, respectively. The median survival time was 20 months for AA patients and 15 months for GB patients. Among AA patients, recurrences were central in 68.7% of patients; in-field, 18.8%; and distant, 12.5%, while among GB patients, 69.0% of recurrences were central, 15.5% were in-field, 12.1% were marginal, and 3.4% were distant. The MIB-1 LI medians were 18.2% in AA and 29.8% in GB. Interestingly, in patients with GB, the MIB-1 LI had a strong effect on the pattern of failure (P = 0.014), while the extent of surgical removal (P = 0.47) and regimens of chemotherapy (P = 0.57) did not.ConclusionsMIB-1 LI predominantly affected the pattern of failure in GB patients treated with a multimodal approach, and it might be a useful tool for the management of the disease.

show abstract

“…Nestin expression in brain tumor cells has been reported in schwannomas [48], ependymomas [49,50], neurocytomas [51], adamantinomatous craniopharyngiomas [52], pituitary adenomas [53], medulloblastomas [54][55][56][57][58][59], oligodendrogliomas [60], and glioblastomas [7,8,48,61] (Table 1). Tissue microarrays of 257 brain tumors have revealed frequent nestin expression in gliomas and schwannomas [48].…”

Section: Nestin In Various Types Of Brain Tumorsmentioning

confidence: 99%

“…Human medulloblastoma cell lines [54] and medulloblastoma stem cells [55][56][57][58] express nestin, and secreted protein acidic and rich in cysteine (SPARC) has been shown to induce neuronal differentiation in medulloblastoma cells with elevations of nestin, NeuN, and neurofilament [59]. One study found that oligodendrogliomas express no or weak nestin, but high Olig2 and alpha-internexin [60]. Oligoastrocytomas moderately express nestin, while astrocytoma and glioblastoma strongly express nestin.…”

Section: Nestin In Various Types Of Brain Tumorsmentioning

confidence: 99%

“…Frequent nestin expression [48] Ependymomas Poor progression-free survival and overall survival [49] Neurocytomas [51] N/D Adamantinomatous craniopharyngiomas Expressed in the invasion niche [52] Pituitary adenomas Coexpressed with CD133 [53] Medulloblastomas Expressed in tumor stem cells [55][56][57][58] Oligodendrogliomas [60] N/D Gliomas High grade [7,8] Worse overall survival [48,61] Glioblastomas Infiltration into surrounding tissue [8] Tumor stem cells [72][73][74][75][76][77] N/D: Not determined.…”

Section: Schwannomasmentioning

confidence: 99%

See 1 more Smart Citation

Nestin: Neural Stem/Progenitor Cell Marker in Brain Tumors

Matsuda¹,

Yoshimura²,

Suzuki³

et al. 2013

Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications

View full text Add to dashboard Cite

Alpha-internexin expression in gliomas: relationship with histological type and 1p, 19q, 10p and 10q status

Abstract: INA expression study can be helpful for glioma typing and prognosis determination in combination with other markers. Nevertheless, INA immunohistochemistry cannot replace the genomic analysis to determine 1p19q and 10p10q status.

Cited by 18 publications

References 43 publications

Adult diffuse gliomas produce mRNA transcripts encoding EGFR isoforms lacking a tyrosine kinase domain

Adult diffuse gliomas produce mRNA transcripts encoding EGFR isoforms lacking a tyrosine kinase domain

Patterns of failure after multimodal treatments for high-grade glioma: effectiveness of MIB-1 labeling index

Nestin: Neural Stem/Progenitor Cell Marker in Brain Tumors

Contact Info

Product

Resources

About